FTO regulates centrosome function and mitotic fidelity in cancers with chromosome instability (CIN)

This study reveals that the RNA demethylase FTO localizes to centrosomes to regulate NuMA and KIFC1 for proper spindle assembly and mitotic fidelity, making FTO inhibition a promising therapeutic strategy for selectively targeting cancers with chromosomal instability.

The Gist

The Big Picture: A Broken Construction Site

Imagine a cell is a busy construction site. Every time the site needs to double its size (cell division), it has to build a perfect, symmetrical tower. To do this, it needs a central crane called the centrosome. This crane sends out cables (microtubules) to grab onto the building materials (chromosomes) and pull them apart evenly to the two new towers.

If the crane breaks or the cables get tangled, the building materials end up in the wrong place. This leads to a "construction disaster" where the new towers are unstable. In healthy cells, the site manager usually fixes this or shuts down the project. But in many cancers, the site is already chaotic (a state called Chromosomal Instability, or CIN). These cancer cells are already struggling to keep their towers straight, so they are walking a tightrope.

The Discovery: Finding the "Foreman"

The researchers discovered a specific protein called FTO. For a long time, scientists thought FTO was just a "foreman" who worked inside the office (the nucleus), editing blueprints (RNA) to make sure the instructions were clear.

However, this paper reveals a shocking new fact: FTO also works on the construction site itself. It hangs out right next to the central crane (the centrosome). Its job is to make sure the crane's cables attach correctly to the building materials.

The Problem: When the Foreman is Fired

The team developed a new "tool" (a small molecule drug called RNB-637) that acts like a temporary firing notice for FTO. When they used this tool on cancer cells:

1. The Crane Lost Control: Without FTO, the cables (microtubules) couldn't grab the building materials properly.
2. The Tower Stalled: The cell got stuck in the middle of construction (a phase called prometaphase arrest). It couldn't finish building the new towers.
3. The Collapse: Because the cell was stuck and confused, it either gave up and self-destructed (apoptosis) or tried to finish the job anyway, resulting in a giant, messy, four-legged tower (a process called mitotic slippage).

The Twist: Why Only the "Bad" Sites Fall

Here is the most exciting part. The researchers tested this tool on two types of construction sites:

• Normal Sites (Healthy Cells): These sites had a backup plan. When the foreman (FTO) was fired, the site manager found a way to keep the crane working, or the site just paused safely. The healthy cells survived.
• Chaos Sites (CIN Cancer Cells): These sites were already unstable. They relied heavily on FTO to keep their wobbly cranes from collapsing. When FTO was removed, the chaos sites couldn't recover. They fell apart immediately.

The Analogy: Imagine a tightrope walker (the cancer cell) who is already wobbling. If you gently tap their balance pole (FTO), they fall off. But a person walking on solid ground (a healthy cell) won't even notice the tap. This means the drug is selective: it kills the cancer without hurting the healthy people around it.

The Mechanism: The "Glue" That Holds It Together

How does FTO actually work? The paper suggests FTO acts like a specialized glue for two other important proteins: NuMA and KIFC1.

• Think of NuMA and KIFC1 as the workers who hold the cables in place on the crane.
• Normally, FTO ensures these workers stay glued to the crane.
• When the drug removes FTO, the workers (NuMA and KIFC1) fall off the crane and wander aimlessly around the construction site. Without them, the cables go slack, and the chromosomes get lost.

The Results: A New Hope for Cancer Treatment

The researchers tested this drug in mice with two types of cancer:

1. Leukemia (Blood Cancer): The tumors shrank significantly.
2. Ovarian Cancer: The tumors shrank even more, with some disappearing almost entirely.

Crucially, the mice didn't get sick or lose weight, proving the drug didn't hurt their healthy cells.

Summary

This paper is like finding a weak spot in a villain's armor.

• The Villain: Cancer cells that are already unstable (CIN).
• The Armor: Their ability to survive despite being messy.
• The Weak Spot: They rely on a protein called FTO to keep their chaotic construction sites from falling apart.
• The Weapon: A new drug that removes FTO.
• The Outcome: The cancer cells collapse under their own weight, while healthy cells remain unharmed.

This discovery opens the door to a new type of cancer therapy that specifically targets the "messy" nature of cancer cells, offering a potential cure that is much safer for patients than current treatments.

Technical Summary

1. Problem Statement

• Chromosomal Instability (CIN): CIN is a hallmark of many cancers, characterized by errors in chromosome segregation, aneuploidy, and whole-genome doubling (WGD). Cancers with CIN often exhibit centrosome amplification (CA) and multipolar mitosis.
• Therapeutic Gap: While CIN creates a vulnerability in cancer cells, there is a lack of targeted therapies that selectively exploit this instability without harming normal cells.
• FTO Function: FTO (Fat Mass and Obesity-associated protein) is an RNA demethylase known to regulate m6A modifications. While its role in metabolism and leukemia is established, its specific function in mitotic regulation, centrosome integrity, and its potential as a target for CIN-positive solid tumors remains poorly understood.
• Inhibitor Limitations: Existing FTO inhibitors suffer from poor specificity, low potency, and inadequate pharmacokinetic (PK) properties, hindering their clinical utility.

2. Methodology

The study employed a multi-disciplinary approach combining drug discovery, molecular biology, cell imaging, and in vivo models:

• Drug Discovery & Optimization:
  • Conducted virtual screening and structure-activity relationship (SAR) studies to develop novel small-molecule FTO inhibitors.
  • Identified lead candidates RNB-557 and RNB-637, along with inactive isomer controls (RNB-558 and RNB-638) for target validation.
  • Validated target engagement using Cellular Thermal Shift Assay (CETSA) and recombinant enzymatic assays (IC50 determination).
• Cellular Phenotyping:
  • Treated various cancer cell lines (AML, pancreatic, ovarian, etc.) and normal fibroblasts with inhibitors.
  • Assessed cell cycle progression via Hoechst DNA staining and flow cytometry.
  • Evaluated apoptosis using Annexin V/Propidium Iodide assays.
  • Performed RNA-Seq and RT-qPCR to analyze gene expression changes (specifically mitotic genes like CCNB1).
• Mechanistic Imaging:
  • Used Immunofluorescence (IF) to visualize FTO localization, centrosome structure (Pericentrin), spindle assembly (Tubulin), and key mitotic proteins (NuMA, KIFC1, Aurora Kinase B).
  • Quantified centrosome numbers, chromosome alignment, and mitotic slippage (cells with >4N DNA content).
  • Conducted "washout" experiments to test the reversibility of phenotypic effects.
• In Vivo Efficacy:
  • Established xenograft models in immunodeficient mice: THP-1 (AML) in CB17 SCID mice and OVCAR-3 (ovarian, CIN+) in BALB/c nude mice.
  • Administered RNB-637 orally (twice daily) at varying doses (25, 50, 75 mg/kg) and monitored tumor volume, body weight, and pharmacokinetics.

3. Key Contributions

• Discovery of Centrosomal FTO: The study provides the first evidence that FTO localizes to centrosomes in both human and mouse cells during interphase and mitosis, a finding conserved across species.
• Novel High-Quality Inhibitors: Development of RNB-557 and RNB-637, potent and selective FTO inhibitors with favorable ADME profiles and strong target engagement, overcoming limitations of previous generations.
• Mechanistic Link to Mitosis: Elucidated a direct mechanism where FTO activity is required for the proper localization of NuMA and KIFC1 (kinesin family member) at the centrosome. Inhibition leads to their mislocalization, spindle defects, and chromosome misalignment.
• Synthetic Lethality in CIN: Demonstrated that cancers with Chromosomal Instability (specifically those with Centrosome Amplification) are selectively vulnerable to FTO inhibition, while normal cells are largely unaffected.

4. Key Results

• Inhibitor Characterization: RNB-557 and RNB-637 effectively inhibited recombinant FTO (IC50 < 1 µM) and stabilized cellular FTO (CETSA). They showed potent cytotoxicity against AML (MV-411) and solid tumor lines, whereas inactive isomers had no effect.
• Mitotic Arrest and Slippage: Treatment with RNB-637 caused:
  • Upregulation of CCNB1 (Cyclin B1) and accumulation of cells in prometaphase.
  • Chromosome misalignment and "star-like" centrosome morphology.
  • Dose-dependent induction of apoptosis or mitotic slippage (resulting in polyploidy, >4N DNA content).
• Centrosomal Localization: IF confirmed FTO co-localizes with Pericentrin and Tubulin. Inhibition caused FTO accumulation but disrupted the localization of KIFC1 (diffusing into the cytoplasm) and NuMA (reducing centrosomal levels and forming cytoplasmic foci).
• Reversibility: Washing out the inhibitor rapidly restored KIFC1 and NuMA localization, centrosome distance, and normal cell cycle progression, confirming the effect is on-target and reversible.
• CIN Selectivity:
  • Cell lines with high Centrosome Amplification (e.g., OVCAR-3, BxPC-3, THP-1) showed significantly higher sensitivity (lower EC50) to RNB-637 compared to CIN-negative lines (e.g., U2OS, normal fibroblasts).
  • Normal fibroblasts showed minimal toxicity even at high doses.
• In Vivo Efficacy:
  • THP-1 (AML): RNB-637 (75 mg/kg) achieved 81.7% Tumor Growth Inhibition (TGI) with no toxicity.
  • OVCAR-3 (Ovarian): RNB-637 (75 mg/kg) achieved 90.5% TGI with no detectable toxicity.
  • PK analysis confirmed serum concentrations exceeded the in vitro EC50 throughout the dosing interval.

5. Significance

• New Biological Insight: The study redefines FTO as a critical regulator of centrosome function and mitotic fidelity, linking RNA demethylation directly to the structural integrity of the mitotic spindle via NuMA and KIFC1.
• Therapeutic Strategy: It establishes FTO inhibition as a viable, selective therapeutic strategy for CIN-positive cancers. This approach exploits the "addiction" of CIN tumors to specific mitotic machinery (like KIFC1) that becomes destabilized upon FTO inhibition.
• Clinical Potential: The development of RNB-637, a potent and selective inhibitor with strong in vivo efficacy and a wide therapeutic window (high efficacy in tumors, low toxicity in normal tissue), positions FTO as a promising target for clinical development in hematological malignancies and solid tumors characterized by chromosomal instability.